CD4 and Keratoconjunctivitis sicca: Such activities observed in animal models and in clinical trials demonstrate that Tß4 has the potential to provide clinically meaningful improvements for patients with both dry eye and NK as well as for patients with other ocular surface lesions and pathologies [19].